All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Graybug Vision Inc. reported results from the phase IIb Altissimo study testing GB-102 as a treatment for wet age-related macular degeneration (AMD) that didn't live up to expectations set by the phase I/IIa Adagio study.
